20 October 2023 – The Committee for Medicinal Products for Human Use of the European Medicine Agency has recommended a conditional marketing authorisation in the European Union for Elrexfio (elranatamab) as a monotherapy (used on its own) for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies and whose cancer has worsened since they received their last treatment.

For more information, see here.